Mecka | $60,000,000 | (Jun 3, 2026)
Novellia | $18,000,000 | (Jun 3, 2026)
Plot | $10,000,000 | (Jun 3, 2026)
Certified by Founder
Lodge
Syremis Therapeutics
start up
- 19/12/2025
- Series A
- $165,000,000
Syremis Therapeutics is a clinical-stage biopharmaceutical company developing novel medicines to make a profound impact on the treatment of mental health. The company’s neuropsychiatric pipeline is rooted in emerging and clinically validated mechanisms, including muscarinic M1/M4 agonism and next-generation NMDA antagonism.
- Industry Biotechnology Research
- Website https://syremis.com/
- LinkedIn https://www.linkedin.com/company/syremis-therapeutics/
Related People
Elisabeth KoganFounder
Israel -
ND
CEO and Co-founder of Syremis Therapeutics, a Biotech company developing novel therapies for neuropsychiatric conditions.
Experienced Pharma executive with a successful track record of delivering innovation and growth in the pharmaceutical industry.
Passionate about bringing new solutions to patients to reduce suffering and improve quality of life.
KOSMOS | $5,000,000 | (Jun 3, 2026)
Phosio Corporation | $4,000,000 | (Jun 3, 2026)
StratusGrid | $3,000,000 | (Jun 3, 2026)
Subtle Medical | $33,000,000 | (Jun 3, 2026)
Tavo Biotherapeutics | $17,000,000 | (Jun 3, 2026)
Contraline | $92,500,000 | (Jun 3, 2026)
Gigaton | $26,000,000 | (Jun 3, 2026)
Westmag | $11,000,000 | (Jun 3, 2026)
Inherent | $50,000,000 | (Jun 2, 2026)